|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | ONE JOHNSON & JOHNSON PLAZA |
Address2 |
|
City | NEW BRUNSWICK |
State | NJ |
Zip Code | 08933 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 20686-12
|
||||||||
|
6. House ID# 303480000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Jane Adams |
Date | 1/20/2023 4:29:15 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
- HR 1978/S 912, "Protecting Seniors Through Immunization Act", regarding all provisions
- HR 6007, "To amend title XVIII of the Social Security Act to provide for the expansion of coverage of vaccines under part B of the Medicare program, and for other purposes", regarding all provisions
- H.Res. 446, Expressing support for the goals and ideals of National Stroke Awareness Month, regarding all provisions
- S 610/HR 1667, "The Dr. Lorna Breen Health Care Provider Protection Act", regarding all provisions
- HR 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions
- S 1784/HR 3353, Contact Lens Prescription Verification Modernization Act, regarding all provisions
- HR 5030/S 2706, "The Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act, regarding all provisions
- S 3394, "Emergency Use Transparency Act", regarding all provisions
- HR 3990/S 2047, "No PFAS in Cosmetics Act", regarding all provisions
- HR 8299/S 4386, "To allow for devices with a predetermined change control plan to be marketed without submitting a supplemental application or premarket notification if the changes to such devices are consistent with such plan.", regarding all provisions
- HR 7667/S 4348, "Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act", regarding provisions on accelerated approval and diversity in clinical studies
- HR 5801, "HELP Copays Act", regarding all provisions
- HR 3173/S 3018 - "Improving Seniors Timely Access to Care Act of 2021", regarding all provisions
- S 3799 - "PREVENT Pandemics Act", regarding all provisions
- HR 3932/S 2076 - "PASTEUR Act of 2021", regarding all provisions
- HR 5376 - "Inflation Reduction Act", regarding provisions on drug pricing and provisions related to revenue
- HR 7559 - Prescription Information Modernization Act of 2022, regarding all provisions
- HR 2617 - "Consolidated Appropriations Act, 2023", regarding provisions related to pharmaceuticals, medical devices, mental health, and tax
- Issues related to Dengue
- Issues related to prescription drug pricing
- Issues related to health care pricing transparency
- Issues related to maternal health
- Issues related to frontline health workers
- Issues related to over the counter products
- Issues related to the regulation of cosmetic products
- Issues related to the regulation of dietary supplements
- Issues related to stroke care
- Issues related to counterfeit health care goods
- Issues related to 340B drug pricing program
- Issues related to antimicrobial resistance
- Issues related to the COVID-19 vaccine development, including diversity in clinical trials
- Issues related to Medicare Part D's 6 protected classes
- Issues related to global public health and ending tuberculosis
- Issues pertaining to health equity and social determinants of health
- Issues related to FDA medical device shortage reporting requirements, including implementation of CARES Act requirements
- Issues related to lung cancer screening
- Issues related to clinical research diversity
- Issues related to international harmonization of medical device regulation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
Leif |
Brierley |
|
|
|
Larry |
Camm |
|
|
|
Darrel |
Jodrey |
|
|
|
Deana |
McRae |
|
|
|
Abigail |
Pinkele |
|
|
|
David |
Kavanaugh |
|
|
|
Kelly |
Waters |
|
|
|
Riley |
Swinehart |
|
|
|
Roberto |
Sada |
|
|
|
Amy |
Pellegrino |
|
|
|
Wendy |
Sussman |
|
|
|
Meghan |
Stone |
|
|
|
Timothy |
Swope |
|
|
|
Colleen |
Vivaldi |
|
|
|
Emely |
Sanchez |
|
Intern, HHS OIG: Spring 2016, Intern, CDC CSTLTS: Fall 2017 and Summer 2020, Intern, Rep. Donna Shalala Fall 2019, Intern Senate HELP Committee: Fall 2020 |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
- HR 1319, "The American Rescue Plan Act of 2021", regarding all provisions
- Issues related to NIH Appropriations (LHHS)
- Issues related to HIV/AIDS Ryan White Appropriations (LHHS) and End the Epidemic
- Issues related to funding for USAID Appropriations (SFOPS)
- Issues pertaining to funding for programs that aim to improve maternal health
- Issues pertaining to cross cutting health system strengthening
- Issues related to FDA Appropriations
- Issues related to contact lenses (FSGG)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
|
Kelly |
Waters |
|
|
|
Deana |
McRae |
|
|
|
Jane |
Adams |
|
|
|
Meghan |
Stone |
|
|
|
Abigail |
Pinkele |
|
|
|
Leif |
Brierley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
- HR 2116, "Creating a Respectful and Open World for Natural Hair (CROWN ACT)", regarding all provisions
- S 936, "INFORM Consumers Act", regarding all provisions
- HR 3429/S 1843, "SHOP SAFE Act", regarding all provisions
- S 3416, "Protecting Patients from Counterfeit Medical Devices Act", regarding the expansion of the enforcement authority of the FDA with respect to counterfeit devices
- HR 6207/S 3357, "Humane Cosmetics Act", regarding all provisions
- Issues related to ingredient safety
- Issues related to animal testing and consumer products
- Issues related to counterfeit consumer products
- Issues related to brand protection
- Issues related to e-Commerce
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
|
Roberto |
Sada |
|
|
|
Leif |
Brierley |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
- HR 4800/S 2546, "Reef Safe Act", regarding all provisions
- Issues related to environmental sustainability
- Issues related to recycling and plastics
- Issues related to coral reefs
- Issues related to clean energy
- Issues related to carbon tax
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Waters |
|
|
|
Darrel |
Jodrey |
|
|
|
Riley |
Swinehart |
|
|
|
Roberto |
Sada |
|
|
|
Deana |
McRae |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
- HR 5214, "To amend the Internal Revenue Code of 1986 to permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements.", regarding expenditures from HSAs, FSAs, and health reimbursement arrangements for dietary supplements
- Issues related to Health Spending Accounts & Flexible Spending Accounts
- Issues related to corporate tax provisions of reconciliation bill
- U.S. Treasury policy and negotiating positions related to tax at the Organisation for Economic Co-operation and Development ("OECD")
- Issues related to US Treasury implementation of new corporate alternative minimum tax
- Issues related to WTO TRIPS agreement
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darrel |
Jodrey |
|
|
|
David |
Kavanaugh |
|
|
|
Jane |
Adams |
|
|
|
Abigail |
Pinkele |
|
|
|
Wendy |
Sussman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
- HR 2884/S 1435, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act, regarding all provisions
- Issues related to mandatory supply chain requirements, including under "Buy America"
- Issues related to waiver of WTO TRIPS related to COVID response
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Kavanaugh |
|
|
|
Timothy |
Swope |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
- Issues related to data privacy
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Leif |
Brierley |
|
|
|
Roberto |
Sada |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CIV
16. Specific lobbying issues
- HR 5, "Equality Act", regarding all provisions
- S 264, "Dream Act of 2021", regarding all provisions
- HR 4, "The John Lewis Voting Rights Advancement Act", issues relating to voting rights
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Larry |
Camm |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BNK
16. Specific lobbying issues
- HR 4777/S 2497, "Nondebtor Release Prohibition Act of 2021", regarding all provisions
- HR 2096/S 2472, "Stop Shielding Assets from Corporate Known Liability by Eliminating Non-Debtor Releases Act", regarding all provisions
- Issues related to corporate Chapter 11 bankruptcy filings and divisive mergers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Riley |
Swinehart |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |